Insights
Educational perspectives from the intersection of regenerative medicine, African healthcare innovation, clinical governance, and institutional intelligence.
Editorial Insights
Educational perspectives from regenerative medicine, African healthcare innovation, and institutional intelligence.
An educational overview of how cellular therapies are being explored globally, and what responsible, evidence-based adoption could look like for African healthcare systems.
More Articles
scroll to explore ↓
Health Sovereignty
9 min readA strategic perspective on why African-led healthcare institutions are essential — not merely aspirational — for reducing dependency and building continental health resilience.
Clinical Governance
6 min readHow rigorous clinical governance frameworks establish credibility, protect patients, and advance the long-term legitimacy of regenerative medicine in Africa.
Uzima AI
8 min readHow Atunse is working with KweHealth through the KIARMA initiative to develop AI systems that are culturally informed, clinically responsible, and purpose-built for the unique realities of African healthcare delivery.
Workforce Development
5 min readThe vision for Atunse's workforce development programs and how AI-enabled education is designed to accelerate clinical competency at scale across the continent.
Translational Research
10 min readHow Atunse's research infrastructure is designed to bridge laboratory discovery and clinical application — entirely within an African-led, African-owned framework.
Regenerative Science
11 min readAn honest look at cell therapy, exosomes, gene therapy, and hormone therapy for dementia — what the science shows, what remains unknown, and why Atunse engages with this young field as an informed option without trading in false hope.
More Articles
Health Sovereignty
A strategic perspective on why African-led healthcare institutions are essential — not merely aspirational — for reducing dependency and building continental health resilience.
Clinical Governance
How rigorous clinical governance frameworks establish credibility, protect patients, and advance the long-term legitimacy of regenerative medicine in Africa.
Uzima AI
How Atunse is working with KweHealth through the KIARMA initiative to develop AI systems that are culturally informed, clinically responsible, and purpose-built for the unique realities of African healthcare delivery.
Workforce Development
The vision for Atunse's workforce development programs and how AI-enabled education is designed to accelerate clinical competency at scale across the continent.
Translational Research
How Atunse's research infrastructure is designed to bridge laboratory discovery and clinical application — entirely within an African-led, African-owned framework.
Regenerative Science
An honest look at cell therapy, exosomes, gene therapy, and hormone therapy for dementia — what the science shows, what remains unknown, and why Atunse engages with this young field as an informed option without trading in false hope.
De-identified case reports and clinical data from our regenerative medicine programs — demonstrating real-world outcomes.
A 32-year-old male sustained a severe alkali (cement) burn to the left eye, presenting at day 7 with a Roper-Hall Grade IV / Dua Grade IV–V injury — the highest severity category, carrying a very poor prognosis. Following topical application of a perinatal-tissue-derived extracellular vesicle preparation, the day-6 examination documented marked improvement in corneal clarity, limbal epithelial stem cell status, and functional vision, with the injury reclassified to Roper-Hall Grade II / Dua Grade II–III.
Outcome
At day 6, reclassification from Roper-Hall Grade IV to Grade II, with corneal clearing, resolved periorbital and malar oedema, estimated limbal epithelial stem cell recovery improving from <25% to >75%, and functional vision improving from <5% to >35%.
At 12-month follow-up: resting pain (VAS) improved from 5/10 at baseline to 0/10, with pain-free status clinically confirmed; Lower Extremity Functional Index improved from 64/80 at baseline to 69/80; musculoskeletal ultrasound showed a smoother, more organised cortical contour and reduced periarticular heterogeneity relative to baseline; no adverse events recorded at any time point.
Transition from a stalled, non-healing full-thickness wound (0% functional skin coverage, necrotic tissue) to healthy granulation tissue with active epithelial migration and a trajectory toward full closure; treating team reported epithelialisation of 12–15% per day against a standard-of-care expectation of 1–2% per day, with 70–80% functional skin coverage reported as early as day 6 after treatment initiation.
Within 24 hours and without systemic intervention, documented resolution of facial and periorbital swelling and rash; periorbital swelling observed to decrease within hours of the first application; no blistering observed; no adverse events recorded. The treating clinician noted an observed symptom course of under one day, against a typical disease course of approximately four weeks for comparable presentations.
At 4 days following a single microneedling-assisted application, visible reduction in inflammatory acne lesions and improved skin clarity were documented photographically, with no adverse events reported.
In interim observations from an ongoing evaluation, instrument-measured improvement was seen across all seven assessed parameters after one month: reductions in wrinkles, acne, dark spots, sebum, blackheads, and sensitivity (lower = better), and an increase in collagen fibre. The device returned an estimated skin-age reduction of more than seven years.
As reported in the published case report: pain decreased from 10/10 to 2/10 within 45 minutes of the first application; the previously proposed skin grafting was determined to be no longer necessary; recovery time was reduced relative to the initial two-month estimate; the patient returned to work 11 days after injury; and skin remodelling with diminished scarring was observed through 3-week and 6-month follow-up.